Several clinical studies have found a decrease of antioxidant (GPx, CAT, and Cu–Zn–SOD) levels and activity in blood of patients with progressive myoclonic epilepsies, showing that the activity of Cu–Zn–SOD in patients was lower than in controls. The gene discussed is SOD1; the disease is progressive myoclonus epilepsy.